These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 30563166)

  • 1. Demethoxycurcumin-Loaded Chitosan Nanoparticle Downregulates DNA Repair Pathway to Improve Cisplatin-Induced Apoptosis in Non-Small Cell Lung Cancer.
    Chen YY; Lin YJ; Huang WT; Hung CC; Lin HY; Tu YC; Liu DM; Lan SJ; Sheu MJ
    Molecules; 2018 Dec; 23(12):. PubMed ID: 30563166
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Demethoxycurcumin sensitizes the response of non-small cell lung cancer to cisplatin through downregulation of TP and ERCC1-related pathways.
    Lin CY; Hung CC; Wang CCN; Lin HY; Huang SH; Sheu MJ
    Phytomedicine; 2019 Feb; 53():28-36. PubMed ID: 30668408
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dual drug-loaded biofunctionalized amphiphilic chitosan nanoparticles: Enhanced synergy between cisplatin and demethoxycurcumin against multidrug-resistant stem-like lung cancer cells.
    Huang WT; Larsson M; Lee YC; Liu DM; Chiou GY
    Eur J Pharm Biopharm; 2016 Dec; 109():165-173. PubMed ID: 27793756
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Forming of demethoxycurcumin nanocrystallite-chitosan nanocarrier for controlled low dose cellular release for inhibition of the migration of vascular smooth muscle cells.
    Wang YJ; Lin HY; Wu CH; Liu DM
    Mol Pharm; 2012 Aug; 9(8):2268-79. PubMed ID: 22788791
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SNHG7 mediates cisplatin-resistance in non-small cell lung cancer by activating PI3K/AKT pathway.
    Chen K; Abuduwufuer A; Zhang H; Luo L; Suotesiyali M; Zou Y
    Eur Rev Med Pharmacol Sci; 2019 Aug; 23(16):6935-6943. PubMed ID: 31486493
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synergistic effect of curcumin and cisplatin via down-regulation of thymidine phosphorylase and excision repair cross-complementary 1 (ERCC1).
    Tsai MS; Weng SH; Kuo YH; Chiu YF; Lin YW
    Mol Pharmacol; 2011 Jul; 80(1):136-46. PubMed ID: 21493726
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Co-treatment with BEZ235 enhances chemosensitivity of A549/DDP cells to cisplatin via inhibition of PI3K/Akt/mTOR signaling and downregulation of ERCC1 expression.
    Xia A; Li H; Li R; Lu L; Wu X
    Oncol Rep; 2018 Oct; 40(4):2353-2362. PubMed ID: 30066933
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Demethoxycurcumin-carrying chitosan-antibody core-shell nanoparticles with multitherapeutic efficacy toward malignant A549 lung tumor: from in vitro characterization to in vivo evaluation.
    Huang WT; Larsson M; Wang YJ; Chiou SH; Lin HY; Liu DM
    Mol Pharm; 2015 Apr; 12(4):1242-9. PubMed ID: 25760774
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Over-regulation of microRNA-133b inhibits cell proliferation of cisplatin-induced non-small cell lung cancer cells through PI3K/Akt and JAK2/STAT3 signaling pathway by targeting EGFR.
    Li B; Ding CM; Li YX; Peng JC; Geng N; Qin WW
    Oncol Rep; 2018 Mar; 39(3):1227-1234. PubMed ID: 29344640
    [TBL] [Abstract][Full Text] [Related]  

  • 10. LncRNA BC200 regulates the cell proliferation and cisplatin resistance in non-small cell lung cancer via PI3K/AKT pathway.
    Gao BB; Wang SX
    Eur Rev Med Pharmacol Sci; 2019 Feb; 23(3):1093-1101. PubMed ID: 30779077
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Knockdown of KLF5 suppresses hypoxia-induced resistance to cisplatin in NSCLC cells by regulating HIF-1α-dependent glycolysis through inactivation of the PI3K/Akt/mTOR pathway.
    Gong T; Cui L; Wang H; Wang H; Han N
    J Transl Med; 2018 Jun; 16(1):164. PubMed ID: 29898734
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PARP inhibition selectively increases sensitivity to cisplatin in ERCC1-low non-small cell lung cancer cells.
    Cheng H; Zhang Z; Borczuk A; Powell CA; Balajee AS; Lieberman HB; Halmos B
    Carcinogenesis; 2013 Apr; 34(4):739-49. PubMed ID: 23275151
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bisdemethoxycurcumin sensitizes cisplatin-resistant lung cancer cells to chemotherapy by inhibition of CA916798 and PI3K/AKT signaling.
    Wang HJ; Yang ZX; Dai XT; Chen YF; Yang HP; Zhou XD
    Apoptosis; 2017 Sep; 22(9):1157-1168. PubMed ID: 28677094
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Demethoxycurcumin mediated targeting of MnSOD leading to activation of apoptotic pathway and inhibition of Akt/NF-κB survival signalling in human glioma U87 MG cells.
    Kumar R; Lal N; Nemaysh V; Luthra PM
    Toxicol Appl Pharmacol; 2018 Apr; 345():75-93. PubMed ID: 29510157
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emodin enhances cisplatin-induced cytotoxicity via down-regulation of ERCC1 and inactivation of ERK1/2.
    Ko JC; Su YJ; Lin ST; Jhan JY; Ciou SC; Cheng CM; Chiu YF; Kuo YH; Tsai MS; Lin YW
    Lung Cancer; 2010 Aug; 69(2):155-64. PubMed ID: 19962780
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of thymidine phosphorylase expression by using an HSP90 inhibitor potentiates the cytotoxic effect of cisplatin in non-small-cell lung cancer cells.
    Weng SH; Tseng SC; Huang YC; Chen HJ; Lin YW
    Biochem Pharmacol; 2012 Jul; 84(1):126-36. PubMed ID: 22480737
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FOXO1 and FOXO3a sensitize non-small-cell lung cancer cells to cisplatin-induced apoptosis independent of Bim.
    Sun T; Zhang J; Deng B; Fan X; Long T; Jin H; Tao S; Kang P; Tan Q
    Acta Biochim Biophys Sin (Shanghai); 2020 Dec; 52(12):1348-1359. PubMed ID: 33167006
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of PDGFR by CP-673451 induces apoptosis and increases cisplatin cytotoxicity in NSCLC cells via inhibiting the Nrf2-mediated defense mechanism.
    Yang Y; Deng Y; Chen X; Zhang J; Chen Y; Li H; Wu Q; Yang Z; Zhang L; Liu B
    Toxicol Lett; 2018 Oct; 295():88-98. PubMed ID: 29857117
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Demethoxycurcumin increases the sensitivity of cisplatin-resistant non-small lung cancer cells to cisplatin and induces apoptosis by activating the caspase signaling pathway.
    Chen Y; Hong C; Chen X; Qin Z
    Oncol Lett; 2020 Nov; 20(5):209. PubMed ID: 32963615
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IL-6 signaling contributes to cisplatin resistance in non-small cell lung cancer via the up-regulation of anti-apoptotic and DNA repair associated molecules.
    Duan S; Tsai Y; Keng P; Chen Y; Lee SO; Chen Y
    Oncotarget; 2015 Sep; 6(29):27651-60. PubMed ID: 26313152
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.